Bacterial Vaginosis Market Report 2026

The bacterial vaginosis market size has grown strongly in recent years. It will grow from $3.31 billion in 2025 to $3.62 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing prevalence of bacterial vaginosis among women, wider access to gynecological healthcare services, availability of oral and topical antibiotics, expansion of diagnostic laboratory services, rising clinical screening initiatives.

The bacterial vaginosis market size is expected to see strong growth in the next few years. It will grow to $5.13 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing development of microbiome-based therapies, growing adoption of rapid molecular diagnostics, rising focus on preventive women’s health, expansion of telehealth-supported diagnosis, increasing investment in non-antibiotic treatment alternatives. Major trends in the forecast period include increasing adoption of point-of-care diagnostic tests, rising demand for targeted antibiotic therapies, growing awareness of vaginal microbiome health, expansion of home-based testing solutions, enhanced focus on early detection and screening.

The rising prevalence of sexually transmitted infections (STIs) is expected to propel the growth of the bacterial vaginosis market in the coming years. Sexually transmitted infections (STIs) are infections primarily transmitted through sexual contact and can be caused by bacteria, viruses, or parasites. The growing incidence of STIs is attributed to factors such as unprotected sexual activity, multiple sexual partners, lack of awareness, and antibiotic resistance. Bacterial vaginosis increases vulnerability to STIs by disturbing the vaginal bacterial balance, facilitating the establishment of infections such as HIV and chlamydia. For example, according to the European Centre for Disease Prevention and Control (ECDC), a Sweden-based government agency, gonorrhea cases increased from 70,881 in 2022 (17.9 per 100,000) to 96,969 in 2023 (25 per 100,000), representing a 31% year-on-year rise. Meanwhile, syphilis cases grew from 35,391 in 2022 (8.5 per 100,000) to 41,051 in 2023 (9.9 per 100,000), marking a 13% increase. Chlamydia notifications reached 230,199 in 2023, showing a 3% rise in the crude notification rate compared to 2022. Consequently, the rising incidence of sexually transmitted infections (STIs) is driving the growth of the bacterial vaginosis market.

Major companies in the bacterial vaginosis market are concentrating on developing innovative approaches, such as paired prescription regimens for sexual partners, to secure a competitive edge. Paired prescription regimens involve providing treatment not only to the affected individual but also to their sexual partner, targeting the risk of recurrence at its source. For example, in March 2025, Wisp, a U.S.-based women’s telehealth company, introduced the first-ever Male BV Partner Treatment, a two-part prescription regimen consisting of oral metronidazole and topical clindamycin for male partners. It includes synchronized dual treatment, once-daily administration for seven days, and delivery through Wisp’s telemedicine platform. This approach utilizes emerging clinical evidence to lower reinfection rates and supports the move toward more comprehensive, relationship-focused care, though it may increase regulatory complexity and raise concerns about partner adherence.

In July 2024, Evofem Biosciences, a US-based biopharmaceutical company, acquired the US commercial women's health specialty business from Lupin Limited for $84 million. This acquisition is intended to expand Evofem Biosciences' portfolio in women's health by adding an FDA-approved treatment for bacterial vaginosis and trichomoniasis. Lupin Limited is an India-based pharmaceutical company that focuses on the development and distribution of a broad range of healthcare products, including women's health specialty products.

Major companies operating in the bacterial vaginosis market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Viatris Inc., Organon & Co., Shionogi & Company Limited, Otsuka Pharmaceutical Co. Ltd., Melinta Therapeutics Inc., Evofem Biosciences Inc., Gedea Biotech AB, Hologic Inc., bioMérieux SA, Becton Dickinson and Company, Thermo Fisher Scientific Inc., Roche Holding AG, Abbott Laboratories, Ferring Pharmaceuticals, Mylan N.V., Almirall S.A.

North America was the largest region in the bacterial vaginosis market in 2025. The regions covered in the bacterial vaginosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bacterial vaginosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the bacterial vaginosis market by raising costs of imported diagnostic kits, PCR reagents, pharmaceutical ingredients, and laboratory consumables used in testing and treatment. Healthcare providers in North America and Europe are most affected due to dependence on imported diagnostics and antibiotics, while Asia-Pacific faces increased production costs for test kits. These tariffs are contributing to higher diagnostic and treatment expenses. At the same time, they are encouraging local manufacturing of diagnostic products, domestic pharmaceutical formulation, and regional supply chain development, improving long-term accessibility.

The bacterial vaginosis market research report is one of a series of new reports that provides bacterial vaginosis market statistics, including bacterial vaginosis industry global market size, regional shares, competitors with a bacterial vaginosis market share, detailed bacterial vaginosis market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial vaginosis industry. This bacterial vaginosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bacterial vaginosis (BV) is a common vaginal infection that occurs due to an imbalance in the naturally occurring bacteria, resulting in a reduction of lactobacilli and an overgrowth of anaerobic bacteria. It is marked by symptoms such as a fishy odor, thin grayish-white discharge, and vaginal discomfort, although some cases may show no symptoms.

The primary categories of bacterial vaginosis include point-of-care testing, laboratory testing, and other methods. Point-of-care testing (POCT) involves medical diagnostic procedures performed at or close to the patient’s location, delivering quick results for prompt clinical decision-making. Available products cater to individuals under 15 years, those between 15-45 years, and other age groups. Applications consist of antibiotics and other treatments, utilized by a range of end users including hospitals, homecare services, specialty clinics, and more.

The bacterial vaginosis market includes revenues earned by entities by providing services such as wet mount microscopy, pH testing, and dietary recommendations. The market value includes the value of related goods sold by the service provider or included within the service offering. The bacterial vaginosis (BV) market consists of sales of oral and topical antibiotics, probiotics, pH balancers, gels, and creams. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.